Related Experiment Videos
A single-blind randomized comparison of the 24-h antianginal efficacy of celiprolol versus atenolol
Journal of Cardiovascular Pharmacology
|January 1, 1986
Insights
Celiprolol, a beta-blocker, effectively treats chronic stable angina. Both 200 mg and 400 mg doses of celiprolol showed equal efficacy to atenolol in improving angina symptoms and exercise performance.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic stable angina pectoris is a common cardiovascular condition.
- Beta-blockers are a cornerstone therapy for angina management.
Purpose of the Study:
- To compare the antianginal efficacy of celiprolol with atenolol.
- To evaluate the effects of different celiprolol dosages on angina symptoms and exercise tolerance.
Main Methods:
- A randomized study involving 19 male patients with chronic stable angina.
- Patients received once-daily doses of celiprolol (200 mg or 400 mg) or atenolol (100 mg).
- Outcomes measured included angina attack rates and treadmill exercise performance.
Main Results:
- All three treatment groups demonstrated equal improvements in angina attack frequency.
- Treadmill exercise performance was similarly enhanced across all treatment arms.
- Celiprolol was found to be as effective as atenolol in managing angina.
Conclusions:
- Celiprolol is a viable and effective antianginal agent for long-term use.
- The study supports the use of celiprolol as an alternative to atenolol in angina treatment.
- Both dosages of celiprolol provided comparable therapeutic benefits.
Abstract:
The effects of once-daily dosing with celiprolol 200 mg, celiprolol 400 mg, and atenolol 100 mg have been studied in 19 male patients with chronic stable angina pectoris. All three treatments improved angina attack rates and treadmill exercise performance equally. Celiprolol appears to be as efficacious as atenolol as an antianginal agent during long-term therapy.